Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shaji Kumar, Simon J. Harrison, Michele Cavo, Javier de La Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Francesca Gay, Gabor Mikala, Elizabeth Punnoose, Wan-Jen Hong, Anjla Sood, Muhammad Jalaluddin, Jeremy A. Ross, James M Pauff, Paulo Cesar Maciag, Philippe Moreau
Institutions: Mayo Clinic, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, University of Bologna, Hospital Universitario Doctor Peset, University College Hospital, University College London Hospitals NHS Foundation Trust, University College London, Duke University, Duke Medical Center, São Germano Oncologia, Asklepios Klinik Altona, Asklepios, Japanese Red Cross Medical Center, Seoul National University, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Genentech, AbbVie (United States), Centre Hospitalier Universitaire de Nantes
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AbbVie
OpenAlex ID: W3029267496